

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 3, 2025

**MIMEDX GROUP, INC.**

(Exact name of registrant as specified in charter)

**Florida**  
(State or other jurisdiction  
of incorporation)

**001-35887**  
(Commission  
File Number)

**26-2792552**  
(IRS Employer  
Identification No.)

**1775 West Oak Commons Ct., NE, Marietta GA 30062**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (770) 651-9100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	MDXG	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Important Cautionary Statement**

This report includes forward-looking statements. Statements regarding: (i) future sales or sales growth; (ii) our 2025 and longer term financial goals and expectations for future financial results, including levels of net sales, Adjusted EBITDA, Adjusted EBITDA margin, corporate expenses and cash; (iii) our expectations regarding the placental tissue market; (iv) our expectations regarding Medicare spending; and (v) continued growth in different care settings, are forward-looking statements. Additional forward-looking statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “goal,” “outlook,” “potential,” “will,” “preliminary,” and similar expressions, and are based on management’s current beliefs and expectations.

Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, the reimbursement environment and many other factors; (ii) the Company may change its plans due to unforeseen circumstances; (iii) the results of scientific research are uncertain and may have little or no value; (iv) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship; (v) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies; and (vi) we may alter the timing and amount of planned expenditures for research and development based regulatory developments. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this report and the Company assumes no obligation to update any forward-looking statement.

**Item 7.01 Regulation FD Disclosure.**

MiMedx Group, Inc. (the “Company”) is expected to participate in the Cantor Global Healthcare Conference on September 3, 2025 and has updated its investor presentation. A copy of the presentation materials is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.

The information in this Current Report, including Exhibits 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
99.1	<a href="#">Investor Slide Presentation dated September 3, 2025</a>
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

**SIGNATURES**

Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MIMEDX GROUP, INC.**

September 3, 2025

By: /s/ Doug Rice  
Doug Rice  
Chief Financial Officer

---



# Investor Presentation

Cantor Global Healthcare Conference

September 3, 2025

---

# Disclaimer & Cautionary Statements



This presentation and our earnings call includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such forward-looking statements include statements regarding:

- Growing expansion outside of the U.S.;
- Our growth expectations in 2025 and beyond, including our growth in surgery, increased funding in targeted research and expanded product portfolio;
- Expected results of research and development, including that our efforts will innovate and diversify our product portfolio;
- Placental-derived products and their potential clinical benefits;
- Expectations regarding the reimbursement environment for the Company's products, including Medicare Spending;
- Expectations regarding HELIOGEN and AMNIOEFFECT driving Surgical growth;
- CELERA's impact on retaining business and its impact on our financial results;
- Our expectations that we will continue to advocate for Medicare spending reform;
- Exposure to tariffs and the anticipation that they will not impact the Company's results;
- 2025 full-year revenue growth and Adjusted EBITDA margin, our Long-term non-GAAP effective tax rates and top-line growth post reform in Medicare spending;
- Our ability to manage Private Office dynamics, including adjusting our strategy to remain competitive; and
- The Company's long-term strategy and goals for value creation, the status of its pipeline products, expectations for future products, and expectations for future growth and profitability

Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include:

- Future sales are uncertain and are affected by competition, access to customers, patient access to hospitals and healthcare providers, the reimbursement environment and many other factors;
- The future market for the Company's products can depend on regulatory approval of such products, which might not occur at all or when expected, and is based in part on assumptions regarding the number of patients who elect less acute and more acute treatment than the Company's products, market acceptance of the Company's products, and adequate reimbursement for such therapies;
- The process of obtaining regulatory clearances or approvals to market a biological product or medical device from the FDA or similar regulatory authorities outside of the U.S. is costly and time consuming, and such clearances or approvals may not be granted on a timely basis, or at all, and the ability to obtain the rights to market additional, suitable products depends on negotiations with third parties which may not be forthcoming; and
- The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this presentation and the Company assumes no obligation to update any forward-looking statement.

## A Pioneer and Leader Focused on Helping Humans Heal



**Our vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life.**



Over a decade of experience helping clinicians manage chronic and other hard-to-heal wounds



Leading the industry with innovative products and robust supporting clinical data



Poised to capitalize on favorable market trends to drive top line growth and profitability

## Favorable Demographic Trends

## Increasing Clinical Evidence Expanding Potential For Products

<p><b>10+</b> million people</p>	<p><b>~16%</b> of Medicare beneficiaries</p>	<p><b>Ineffective Wound Management Leads to Poor Outcomes</b></p>	<p><b>Advances Driving Improved Outcomes for Wound Patients</b></p>	<p><b>Emerging Opportunities in Surgical Setting</b></p>
<p>Population suffering from chronic, non-healing wounds in the U.S.<sup>1</sup>, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers and more.</p>	<p>Population is impacted by chronic wounds—and this proportion is increasing.<sup>1</sup></p>	<p>It is estimated that up to <b>85% of amputations are avoidable</b> with a holistic multispecialty team approach that incorporates <b>innovative treatments</b> and adherence to treatment parameters.<sup>2</sup></p>	<p>When applied following parameters for use, patients treated with <b>EPIFIX®</b> experienced reductions in <b>major amputations</b> and <b>hospital utilization</b>.<sup>2</sup></p>	<p>MIMEDX products are available in all settings where patients receive care, <b>increasingly used in a variety of surgical settings</b>, representing incremental market opportunities.</p>

1) Sen DK. Human Wound and Its Burden: Updated 2022 Compendium of Estimates. Adv Wound Care (New Rochelle). 2023;12(12):657-670.  
2) Tettelbach WH, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment. J Wound Care. 2022 Feb 1;31(Sup2):S10-S31.

## National Network of Birthing Center Partners



Expectant Mothers Introduced to Donation Program



Consent for Donation Obtained



Delivery of Healthy Baby via Caesarean Section



Donated Placental Tissues Recovered



Tissues Transported to MIMEDX



Donor Tissue Tested & Prepared for Manufacturing

## Proprietary Processing Backed by Broad Portfolio of Intellectual Property

**Purion**

Proprietary Processing & Terminal Sterilization of Tissues



Shelf-Stable, Packaged Product Available to Ship



Robust IP Estate with 200+ Patents



Significant Opportunity for Continued Scale

## Ample Placental Supply and Manufacturing Capabilities to Support Continued Growth and Industry Demand

# The Patient Journey in Wound Care



**MIMEDX products are available throughout the continuum of care and are used on a range of chronic and other hard-to-heal wounds.**



**AMNIOEFFECT in High-Risk Vascular**  
E-Published April 2025  
*Vascular*



**EPIFIX in Mohs (HECON)**  
Published May 2025  
*Journal of Drugs in Dermatology*



**AMNIOFIX in GI Anastomosis**  
Manuscript Pending




**AMNIOFIX in Liver Transplant**  
RCT Enrollment Underway





**AMNIOFIX in Breast Reduction**  
RCT Enrollment Underway

Generating Clinical Data in Numerous Surgical Disciplines Incorporating Use of MIMEDX Products



### LTM Sales Mix by Product Type



# Strategic Priorities Position Us to Win in 2025 & Beyond

1

## Innovate & Diversify Product Portfolio to Maximize Growth

Enrollment continues for EPIEFFECT RCT with plans for interim report out

Received TRG letter for our latest innovation, EPIXPRESS, clearing way for launch later this year

Pilot programs underway for non-skin substitute Wound products, including with Vaporox

2

## Develop & Deploy Programs to Expand Surgical Footprint

Study on cost effectiveness of using MIMEDX products following Mohs surgery published in May in *Journal of Drugs in Dermatology*

AMNIOFIX & AMNIOEFFECT continues to see strong uptake in surgical setting

HELIOGEN sales accelerating with promising trajectory

3

## Enhance Customer Intimacy

Evolving market dynamics place greater importance on comprehensive value offering, providing opportunity for MIMEDX Connect to drive stickiness

Continue to develop programs and initiatives to further drive customer intimacy

# Experienced, Skillful Leadership Team Executing Strategy



## Management Team with Track Record of Success in MedTech



**Joe Capper**  
Chief Executive Officer



**Doug Rice**  
Chief Financial Officer



**Butch Hulse**  
Chief Administrative Officer & General Counsel



**Kim Moller**  
Chief Commercial Officer



**Ricci Whitlow**  
Chief Operating Officer



**John Harper, Ph.D.**  
Chief Scientific Officer & SVP, R&D



**Matt Notarianni**  
Head of IR

### Prior Roles Include:



